A Prospective Comparison of 3 Approved Systems for Autologous Bone Marrow Concentration Demonstrated Nonequivalency in Progenitor Cell Number and Concentration

Hegde, Vishal; Shonuga, Owolabi; Ellis, Scott; Fragomen, Austin T.; Kennedy, John G.; Kudryashov, Valery; Lane, Joseph M.

doi:10.1097/bot.0000000000000113

Cited by 69 publications

(68 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hegde et al compared the Magellan to two other FDA-approved bone marrow concentration systems, namely Harvest SmartPrep 2 (Harvest Technologies Corporation, Plymouth, MA) and Biomet BioCUE (Biomet Biologics, Warsaw, IN), for their capacity to isolate progenitor cells from BMA of iliac crest in humans. The SmartPrep 2 system resulted in a greater concentration of progenitor cells, evaluated by means of a CFU-F assay, when compared to the Biomet and the Magellan system [25]. Cassano et al performed extensive comparison on the composition of human BMC and platelet-rich plasma using also the Magellan and the SmartPrep 2.…”

Section: Discussionmentioning

confidence: 99%

Quantitative Assessment of Optimal Bone Marrow Site for the Isolation of Porcine Mesenchymal Stem Cells

McDaniel

Antebi

Pilia

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

Background. One of the most plentiful sources for MSCs is the bone marrow; however, it is unknown whether MSC yield differs among different bone marrow sites. In this study, we quantified cellular yield and evaluated resident MSC population from five bone marrow sites in the porcine model. In addition, we assessed the feasibility of a commercially available platelet concentrator (Magellan® MAR01™ Arteriocyte Medical Systems, Hopkinton, MA) as a bedside stem cell concentration device. Methods. Analyses of bone marrow aspirate (BMA) and concentrated bone marrow aspirate (cBMA) included bone marrow volume, platelet and nucleated cell yield, colony-forming unit fibroblast (CFU-F) number, flow cytometry, and assessment of differentiation potential. Results. Following processing, the concentration of platelets and nucleated cells significantly increased but was not significantly different between sites. The iliac crest had significantly less bone marrow volume; however, it yielded significantly more CFUs compared to the other bone marrow sites. Culture-expanded cells from all tested sites expressed high levels of MSC surface markers and demonstrated adipogenic and osteogenic differentiation potential. Conclusions. All anatomical bone marrow sites contained MSCs, but the iliac crest was the most abundant source of MSCs. Additionally, the Magellan can function effectively as a bedside stem cell concentrator.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative Assessment of Optimal Bone Marrow Site for the Isolation of Porcine Mesenchymal Stem Cells

McDaniel

Antebi

Pilia

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…The BMC may also be prepared manually in a sterile glass or plastic blood-collection tube with a closure that is evacuated to create a vacuum inside the tube, facilitating the draw of the predetermined BMA; however, no data exists comparing mononuclear cell counts using either the centrifuge or blood-collection tube method. As mentioned previously, it is now known that the various commercially available centrifuge systems may not generate equivalent amounts of HSCs and progenitor cells; however, this may be due to differences in the bone marrow acquisition process [77]. Kon et al recently presented data at the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS) 2013 meeting reporting that BMC cell counts are superior to those of BMA; however, clinical superiority remains polemical [78].…”

Section: Bmc Preparationmentioning

confidence: 99%

Clinical Aspects of Regenerative Medicine

Sampson

Bemden

Aufiero

2015

Translational Regenerative Medicine

View full text Add to dashboard Cite

“…33 Using more contemporary techniques such as flow cytometry to simultaneously evaluate several cell surface markers in the aspirate as opposed to separated and cultured cell populations, it is more relevant to state that a standard 4 to 6 mL of BMC generated from centrifugation of 60 mL of BMA will contain approximately 40,000 MSCs. 19,26,34,35 Defining the actual number of MSCs in BMA is difficult because there is no one set of cell surface markers that can identify the various subpopulations of MSCs in vivo. Great caution should be used when relying solely on CFU to determine or to compare the number of MSCs between products.…”

Section: Does Bmc Contain Enough Mscs To Effectuate Repair?mentioning

confidence: 99%

Biological Effects of Bone Marrow Concentrate in Knee Pathologies

et al. 2018

Self Cite

View full text Add to dashboard Cite

With our aging population desiring to remain active, the incidence and costs associated with managing knee pain from both acute injury and symptomatic knee osteoarthritis continue to dramatically increase. Current treatment methods fall short with respect to their ability to improve the intra-articular environment and restore normal joint homeostasis. With increasing basic science and clinical evidence showing efficacy, cell-based therapies such as bone marrow concentrate (BMC) hold promise as a nonsurgical joint preserving treatment approach. BMC has inherent advantages over other treatments commonly used for various knee pathologies because it is a point-of-care orthobiologic product that uniquely and simultaneously delivers growth factors, anti-inflammatory proteins, and mesenchymal stem cells. There is increasing evidence for the use of BMC for repair of focal cartilage defects and for the treatment of generalized knee pain. However, continued high-quality studies are necessary for the clinical utility of BMC to be critically assessed with particular attention paid to appropriate patient selection, standardized aspiration, and processing and reporting of both functional and imaging-based outcomes.

show abstract

A Prospective Comparison of 3 Approved Systems for Autologous Bone Marrow Concentration Demonstrated Nonequivalency in Progenitor Cell Number and Concentration

Abstract: The Harvest system resulted in a greater CTP number and concentration after centrifugation when compared with the Biomet and Arteriocyte systems and may thus provide increased osteogenic and chondrogenic capacity.

Cited by 69 publications

References 34 publications

Quantitative Assessment of Optimal Bone Marrow Site for the Isolation of Porcine Mesenchymal Stem Cells

Quantitative Assessment of Optimal Bone Marrow Site for the Isolation of Porcine Mesenchymal Stem Cells

Clinical Aspects of Regenerative Medicine

Biological Effects of Bone Marrow Concentrate in Knee Pathologies

Contact Info

Product

Resources

About